Bone Biologics Corp (BBLG)

Common Shares

Sell: $1.21|Buy: $1.26|Change: 0.04 (2.92%)

Open

$1.2001

Previous close

$1.20

Trade high

$1.26

Volume

21,689

Year high

$6.75

Year low

$1.05

Dividend yield

–

Market capitalisation

$2.22 mn

P/E ratio

0.09

ISIN

US0980706008

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 07/04/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Bone Biologics Corp	+ 2.92
More...

Company profile

Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.